While several predictors of an early and sustained response can be identified in the treatment of chronic hepatitis B, no consistently demonstrable predictors of response exist for chronic hepatitis C. As such, guidelines for the treatment of chronic hepatitis C are more complex than those for hepatitis B. The treatment options for chronic hepatitis B and C are outlined and there is speculation on the clinical challenges of the future.
Interferons have emerged as the group of antiviral agents with proved efficacy in the treatment of chronic viral hepatitis B and C (HBV and HCV, respectively). For optimum effect, treatment has to be tailored to the patient's needs, taking into consideration the patient's age, the stage of their disease, their motivation, and toleration of the drug.
We are now approaching the stage where the monitoring of treatment by HBV-DNA and HCV-RNA determination should provide a more rational treatment strategy for chronic hepatitis B and C, respectively. Predictors of a favourable response to alpha interferon in hepatitis B and C are shown in the Table. Chronic hepatitis C Guidelines for the treatment of chronic hepatitis C are more complex than those for B. A suggested algorithm for the treatment of chronic hepatitis C is shown in the figure. Treatment should begin with 3 MU interferon three times weekly for three months, and should continue until the HCV-RNA value is negative. The dose should then be decreased to 1 MU three times weekly and treatment continued for one year. If patients relapse when treatment is withdrawn, retreating with the initial regimen is recommended, providing there are no contraindications. In the case of non-responders, where the HCV-RNA value actually increases, the dose of interferon should be increased to 5 MU three times weekly. If, after three months, the HCV-RNA is still showing no signs of a reduction, treatment with interferon should be stopped and another agent considered. Ribavirin and thymosin may have a place in treating chronic hepatitis, either alone or in combination with interferon. Although ribavirin has the advantage of oral administration, studies have not shown an impressive rate of complete response.
Future challenges Although interferons are proved to be effective in the treatment of chronic viral hepatitis B and C, there are still some challenges ahead. Certain situations remain quite difficult, for example the post liver transplant patient who almost inevitably becomes re-infected both in the case of chronic B and chronic C hepatitis. Should we be treating more of these patients before transplantation? Can we use a regimen after transplantation without bringing about rejection? Immunosuppressed people, for example HIV positive patients, are also difficult to treat, as are patients with autoimmune disease. Finally, one of the biggest challenges facing us in the world is the perinatal transmission of viral hepatitis. The vast majority of people who are carriers of HBV were infected in this way, and as a group are relatively refractory to treatment with interferon.
